ImmuPharma plc (LON:IMM – Get Free Report)’s share price dropped 10.1% during mid-day trading on Thursday . The company traded as low as GBX 3.75 and last traded at GBX 4. Approximately 785,293 shares changed hands during mid-day trading, a decline of 70% from the average session volume of 2,605,068 shares. The stock had previously closed at GBX 4.45.
ImmuPharma Price Performance
The business’s 50-day moving average price is GBX 4.15 and its 200 day moving average price is GBX 5.16. The company has a market capitalization of £24.96 million, a P/E ratio of -10.81 and a beta of 3.02.
ImmuPharma (LON:IMM – Get Free Report) last posted its earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share for the quarter. ImmuPharma had a negative return on equity of 353.21% and a net margin of 3,519.56%. Analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- Why These 3 Equal Weight ETFs Have Outperformed the S&P This Year
- MarketBeat Week in Review – 08/03 – 08/07
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
